Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: Real-world data from a single center
Luisa Fernanda Sánchez-Valledor, Thomas M Habermann, Iván Murrieta-Alvarez, Alejandra Carmina Córdova-Ramírez, Montserrat Rivera-Álvarez, Andrés León-Peña, Yahveth Cantero-Fortiz, Juan Carlos Olivares-Gazca, Guillermo José Ruiz-Delgado, Guillermo José Ruiz-Argüelles
Luisa Fernanda Sánchez-Valledor, Escuela de Medicina, Universidad de las Américas Puebla, Cholula 72810, Puebla, Mexico
Thomas M Habermann, Department of Medicine, Division of Hematology, Mayo Clinical and Mayo Foundation, Rochester, MN 55905, United States
Iván Murrieta-Alvarez, Andrés León-Peña, Yahveth Cantero-Fortiz, Juan Carlos Olivares-Gazca, Guillermo José Ruiz-Delgado, Guillermo José Ruiz-Argüelles, Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla 72530, Mexico
Alejandra Carmina Córdova-Ramírez, Montserrat Rivera-Álvarez, Escuela de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, Mexico
Author contributions: Ruiz-Agüelles GJ, Habermann TM and Ruiz-Delgado GJ conceptualized and designed the study; Ruiz-Argüelles GJ, Ruiz-Delgado, Murrieta-Álvarez I wrote the manuscript; Murrieta-Álvarez I, Cantero-Fortiz Y, León-Peña A and Rivera-Álvarez M conducted the analyses; Rivera-Álvarez M, Córdova-Ramírez AC, and Olivares-Gazca JC collected data; All authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Centro de Hematología y Medicina Interna, Clínica Ruiz Institutional Review Board.
Informed consent statement: Informed consent was waived by the Institutional Review Board.
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
Data sharing statement: Data are available upon request.
STROBE statement: The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
http://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Guillermo José Ruiz-Argüelles, FRCP (Glasg), MACP, DSc (hc), FRCP, MD, Professor, Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla 72530, Mexico. gruiz1@hsctmexico.com
Received: January 4, 2021
Peer-review started: January 4, 2021
First decision: May 4, 2021
Revised: May 17, 2021
Accepted: August 9, 2021
Article in press: August 9, 2021
Published online: September 24, 2021
Processing time: 255 Days and 14.3 Hours
BACKGROUND
The outcomes of Hodgkin´s lymphoma (HL) in Mexico have not been widely reported. Simplified and affordable treatments have been adopted in middle-income countries.
AIM
The aim was to evaluate long-used therapies for HL in Mexico in a long-term basis.
METHODS
In a 34-year time period, 88 patients with HL were treated at a single institution in Mexico. Patients were treated with adriamycin bleomycin vinblastine and dacarbazine (ABVD) or mechlorethamine, vincristine, procarbazine, and prednisone (MOPP). Relapsed or refractory patients were given ifosfamide, carboplatin, and etoposide (ICE) followed by autologous or allogeneic stem cell transplants.
RESULTS
Thirty-seven women and 51 men were included; the median age was 29 years. Patients were followed for a mean of 128 mo. The 310-mo overall survival (OS) was 83% for patients treated with MOPP and 88% for those treated with ABVD. The OS of patients who received autologous stem cell transplantation was 76% (330 mo) vs 93% (402 mo) in those who did not.
CONCLUSION
HL may be less aggressive in Mexican population than in Caucasians. Combined chemotherapy renders acceptable results, regardless of clinical stage.
Core Tip: In a retrospective, observational long-term study, our group found that the treatment of Hodgkin lymphoma in a resource-constrained background may still rely on the use of the traditional adriamycin bleomycin vinblastine and dacarbazine treatment regimen in order to achieve acceptable outcomes. The observations were consistent across different stages of disease and may serve to propose new studies focusing on the comparison of newly approved therapies in contexts where there are some healthcare limitations.
